GX P1
Alternative Names: GX-P1; Long acting programmed death-ligand 1 - Genexine; PD-L1 hyfc - GenexineLatest Information Update: 06 Nov 2023
At a glance
- Originator Genexine
- Class Recombinant fusion proteins
- Mechanism of Action Programmed cell death 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autoimmune disorders; Transplant rejection
Most Recent Events
- 06 Nov 2023 GX P1 is still in phase I development in Autoimmune disorders (In volunteers) in South Korea (IV, Infusion) (Genexine pipeline, October 2023)
- 28 Oct 2023 Phase-I clinical trials in Transplant rejection (IV) (Genexine pipeline, October 2023)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in South Korea (IV, Infusion)